STOCKHOLM, Oct. 19, 2018 /PRNewswire/ --
IRRAS AB (Nasdaq First North Premier: IRRAS) announced today
that, as of October 19, the IRRAS
management consists of the following groups and persons:
Executive
Management Team
|
|
Kleanthis G.
Xanthopoulos, Ph.D.
|
President &
CEO
|
Fredrik
Alpsten
|
CFO and Deputy
CEO
|
Will
Martin
|
Chief Commercial
Officier
|
Lance
Boling
|
Vice President,
Product Development
|
Kellie
Fontes
|
Senior Director,
Human Capital
|
Extended
Management Group
|
|
Adam
Sampson
|
Vice President,
Product Excellence
|
Dino De
Cicco
|
Senior Director,
Product Development
|
Dessi
Lyakov
|
Director, Regulatory
& Quality
|
Sabina
Berlin
|
Vice President,
Finance
|
Simultaneously with the above mentioned management changes,
Karl-Matthias Moehlmann, Senior Vice
President, Commercial Operations and General Manager, Europe, has left IRRAS.
For more information, please contact:
US
|
Europe
|
Kleanthis G.
Xanthopoulos, Ph.D.
|
Fredrik
Alpsten
|
President &
CEO
|
CFO and Deputy
CEO
|
|
+46-706-67-31-06
|
info@irras.com
|
fredrik.alpsten@irras.com
|
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a
publicly-traded, commercial-stage medical technology company
focused on developing and commercializing innovative solutions for
brain surgery. The company's initial product, IRRAflow®,
addresses the complications associated with the current methods of
managing intracranial fluid by using a dual lumen catheter that
combines active irrigation with ongoing fluid drainage.
IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the IRRAflow catheter is
automatically flushed to prevent common catheter occlusions from
forming. Because IRRAflow is a completely closed system, it
is designed to reduce the documented infection risk of
these procedures. Additionally, IRRAflow incorporates ICP
monitoring and uses a proprietary software to regulate treatment
based on desired pressure levels.
With its unique product portfolio, protected by property patents
and patent applications, IRRAS is well positioned to establish a
leadership position in the medical device market. IRRAS maintains
its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco
is certified adviser of the company.
This document is considered information that IRRAS is obliged to
disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact person above, on October 19,
2018 at 8.00 a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-expands-its-management-group,c2648583
The following files are available for download:
http://mb.cision.com/Main/16550/2648583/929028.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/irras-expands-its-management-group-300734218.html
SOURCE IRRAS